Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic
about
Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practiceClinical evaluation of a dried blood spot assay for atazanavirAtazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapyPopulation pharmacokinetics of atazanavir in patients with human immunodeficiency virus infectionThe use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria.HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.Acid suppressive therapy and the effects on protease inhibitors.External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.Atazanavir: simplicity and convenience in different scenarios.Factors influencing lopinavir and atazanavir plasma concentration.Therapeutic drug monitoring in highly active antiretroviral therapy.Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery.Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.Correlations between atazanavir C(trough )and hyperbilirubinemia: a case report.Monitoring therapy.Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption.Ulcerogenic and intestinal motility/transit stimulating actions of nevirapine in albino Wistar rats.Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients.Atazanavir/ritonavir: a valuable once-daily HIV protease inhibitor with little impact on lipid profile
P2860
Q33681426-A9DABE7D-597F-4ED7-9D48-C1B398C0D68EQ34150893-9D5CD896-F424-47DF-B284-57F7960AF3F3Q34814795-D2C9A2C9-D200-4B7F-A7E8-88D3E84CCB6CQ35127808-CCEE261D-FFAC-49D0-95A0-85560FAA1708Q35318395-50A87138-ACF3-41FC-9C8D-659D76714830Q36412256-38AEE327-770E-4697-8C4E-F4C8A28D5E43Q36640626-A74D19E0-0554-47EF-84EA-1E3CCDC47482Q36746173-A3D29DFE-7C40-4B60-8F4E-06E83B14F56FQ36765802-7D5E75B7-3ADA-4B37-A48B-2B29CD5B3D94Q37476403-8FAD352F-9F14-45EC-9254-714CAF62C48AQ37720765-58F6FA1B-D620-44F1-AFA9-005225B8039FQ38194964-65E351BB-B14A-4D16-943A-66F0047B28ABQ40603398-32700A5E-5C57-4B12-86D0-8D1BD6A3F523Q41761836-0B0C2399-2398-4890-8854-D1566B230FCFQ42759049-B82F3646-CB7C-48B0-846C-E863E30CD299Q46349067-9BFC261A-8EAE-445E-B007-9D1ED7FB7173Q46499100-0F04A963-DD85-4215-AFB6-874864EDF5ACQ51553332-1ECECFB7-B583-4A14-A58B-1AEEBB55D847Q58291152-FA7FB478-F4E1-4ECF-8A05-C316A4B50DA9
P2860
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic
@ast
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic
@en
type
label
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic
@ast
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic
@en
prefLabel
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic
@ast
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic
@en
P2093
P2860
P1476
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic
@en
P2093
Debbie Marriott
John E Ray
Mark T Bloch
P2860
P304
P356
10.1111/J.1365-2125.2005.02413.X
P407
P577
2005-09-01T00:00:00Z